ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2023
[Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
L H Zhou, Y Q Feng, Y X Hu, H Huang
Open access · greenAbstract readEnglish Abstract
In one paragraphArticle in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors at 1 institution in 1 country.
L H ZhouBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Liangzhu Laboratory, Zhejiang University Medical Center; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou 310003, China.
Y Q FengBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Liangzhu Laboratory, Zhejiang University Medical Center; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou 310003, China.
Y X HuBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Liangzhu Laboratory, Zhejiang University Medical Center; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou 310003, China.
H HuangBone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Liangzhu Laboratory, Zhejiang University Medical Center; Institute of Hematology, Zhejiang University; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou 310003, China.
First Affiliated Hospital Zhejiang University · CN
Funding
National Natural Science Foundation of China 82130003, 82270234Sanming Project of Medicine in Shenzhen SZSM202111004
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Circulating Tumor DNAImmediate-Early ProteinsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinReceptors, Chimeric AntigenCell- and Tissue-Based TherapyFeasibility StudiesHumansMutationPrognosisRetrospective StudiesTumor Suppressor ProteinsBTG2 protein, humanCirculating Tumor DNAImmediate-Early ProteinsReceptors, Chimeric AntigenTumor Suppressor ProteinsChimeric antigen receptor T-cellctDNADiffuse large B-cell lymphomaPrognosis
Identifiers
PMID38049331
PMCPMC10694077
OpenAlexW4389346260
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390